logo-loader
viewPropanc Biopharma Inc

Propanc Biopharma wins US patent to better protect its lead cancer-fighting drug PRP

The patent covers composition of matter claims involving pancreatic proenzymes trypsinogen and chymotrypsinogen -- which together comprise PRP

Propanc Biopharma Inc - Propanc Biopharma wins US patent to better protect its lead cancer-fighting drug PRP
PRP targets and eradicate cancer stem cells in patients suffering from pancreatic, ovarian and colorectal cancers

Propanc Biopharma Inc (OTCMKTS:PPCB), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, saw its shares rise on Wednesday following news the firm has been granted a US patent to better protect its lead drug PRP.

In afternoon trading in New York, shares in Propanc were 7.7% higher at $1.40. 

In a statement, the company said that the patent granted by United States Patent and Trademark Office covers composition of matter claims involving pancreatic proenzymes trypsinogen and chymotrypsinogen -- which together comprise PRP for treating various cancers. The patent is the second one covering PRP. 

Propanc said that in order to win the patent it was able to demonstrate that trypsinogen and chymotrypsinogen exhibit a synergistic ability to inhibit the growth of various cancer cell lines.

READ: Propanc Biopharma publishes promising study of its metastatic cancer drug in peer-reviewed medical journal

“We continue to grow and strengthen our intellectual property portfolio and it is pleasing to receive additional patent claims for PRP in one of our most important global jurisdictions,” CEO James Nathanielsz said in a statement. 

“Presently, we have 65 patents either in force, or pending, in major global regions around the world, and this is very significant as we advance PRP towards human trials.” 

The Australian company says the pancreatic proenzymes target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian and colorectal cancers.

The novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body’s primary defense against cancer.

 -- Adds share price --

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Propanc Biopharma Inc

Price: 0.36 USD

OTCMKTS:PPCB
Market: OTCMKTS
Market Cap: $421.21 k
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Preveceutical announces successful preliminary evaluation of...

Preveceutical (CSE:PREV-OTCQB: PRVCF) President Mak Jawadeker joined Steve Darling from Proactive Vancouver on Skype to discuss the company successfully completing the design, synthesis and preliminary evaluation of key peptides from its scorpion venom-derived peptide research and development...

1 day, 4 hours ago

2 min read